View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AG20 Publication ID: Spring 2017 
Title: Amendment to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals--Second Phase 
Abstract: FDA will revise regulations for "current good manufacturing practice" for oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products. This revision will update and harmonize requirements and improve detection and response to emerging product safety and quality signals.  
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Completed Actions 
Major: Undetermined  Unfunded Mandates: Undetermined 
EO 13771 Designation:  
CFR Citation: 21 CFR 210    21 CFR 211   
Legal Authority: 21 U.S.C. 321    21 U.S.C. 351    21 U.S.C. 352    21 U.S.C. 355    21 U.S.C. 360b    21 U.S.C. 371    21 U.S.C. 374    42 U.S.C. 262    42 U.S.C. 264   
Legal Deadline:  None
Timetable:
Action Date FR Cite
Withdrawn  06/08/2017 
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: No 
International Impacts: This regulatory action will be likely to have international trade and investment effects, or otherwise be of international interest.
RIN Data Printed in the FR: Yes 
Agency Contact:
Paula Katz
Regulatory Counsel, Office of Compliance
Department of Health and Human Services
Food and Drug Administration
Suite 3037 (HFD-7), Center for Drug Evaluation and Research, WO 51, Room 4314, 10903 New Hampshire Avenue,
Silver Spring, MD 20993
Phone:301 796-6972
Fax:301 847-8742
Email: paula.katz@fda.hhs.gov